Mark M. Awad
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 194
- Cancer Immunotherapy and Biomarkers 123
- Lung Cancer Research Studies 41
- Colorectal Cancer Treatments and Studies 24
- Peptidase Inhibition and Analysis 14
- Pancreatic and Hepatic Oncology Research 10
-
- Lung Cancer Treatments and Mutations 121
- Lung Cancer Diagnosis and Treatment 36
- Co-authors
- Alice T. Shaw (10 shared papers)Lynette M. Sholl (61 shared papers)Mizuki Nishino (49 shared papers)Pasi A. Jänne (29 shared papers)Biagio Ricciuti (84 shared papers)F. Stephen Hodi (16 shared papers)Suzanne E. Dahlberg (10 shared papers)Justin F. Gainor (22 shared papers)
- Journals
- Journal of Clinical Oncology (95 papers)Journal of Thoracic Oncology (36 papers)Annals of Oncology (24 papers)Cancer Research (16 papers)JCO Precision Oncology (10 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Mark M. Awad
260 papers receiving 11.0k citations
Mark M. Awad's Hit Papers
Peers
Comparison fields: 5 of 110
- Oncology 6.5k
- Pulmonary and Respiratory Medicine 4.4k
- Cancer Research 1.3k
- Immunology 1.1k
- Hepatology 306
Countries citing papers authored by Mark M. Awad
This map shows the geographic impact of Mark M. Awad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Awad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Awad more than expected).
Fields of papers citing papers by Mark M. Awad
This network shows the impact of papers produced by Mark M. Awad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Awad. The network helps show where Mark M. Awad may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark M. Awad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 283 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Hit paper breakdown → | 2016 | 1075 |
| 2 | Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 680 |
| 3 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Hit paper breakdown → | 2020 | 508 |
| 4 | MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression Hit paper breakdown → | 2016 | 499 |
| 5 | ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer Hit paper breakdown → | 2013 | 462 |
| 6 | Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2020 | 438 |
| 7 | Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients Hit paper breakdown → | 2017 | 373 |
| 8 | 2016 | 367 | |
| 9 | 2018 | 301 | |
| 10 | 2018 | 261 | |
| 11 | 2013 | 217 | |
| 12 | 2019 | 206 | |
| 13 | ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. | 2014 | 203 |
| 14 | 2019 | 189 | |
| 15 | 2008 | 179 | |
| 16 | 2006 | 175 | |
| 17 | 2018 | 170 | |
| 18 | 2020 | 147 | |
| 19 | 2004 | 140 | |
| 20 | 2021 | 132 |
About Mark M. Awad
Mark M. Awad is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 283 papers that have together received 11.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (123 papers), Lung Cancer Treatments and Mutations (121 papers), Cancer Genomics and Diagnostics (46 papers), Lung Cancer Research Studies (41 papers), Lung Cancer Diagnosis and Treatment (36 papers), Colorectal Cancer Treatments and Studies (24 papers), Peptidase Inhibition and Analysis (14 papers) and Pancreatic and Hepatic Oncology Research (10 papers). The work is most often cited by research in Oncology (6.5k citations), Pulmonary and Respiratory Medicine (4.4k citations), Cancer Research (1.3k citations), Immunology (1.1k citations) and Hepatology (306 citations). Mark M. Awad has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Alice T. Shaw, Lynette M. Sholl, Mizuki Nishino, Pasi A. Jänne, Biagio Ricciuti, F. Stephen Hodi, Suzanne E. Dahlberg, Justin F. Gainor, James Chih‐Hsin Yang and Hiroto Hatabu. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Cancer Research and JCO Precision Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.